A detailed history of Victory Capital Management Inc transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 12,892 shares of VYGR stock, worth $75,933. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,892
Previous 11,262 14.47%
Holding current value
$75,933
Previous $104,000 2.88%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$7.42 - $10.54 $12,094 - $17,180
1,630 Added 14.47%
12,892 $101,000
Q1 2024

May 03, 2024

BUY
$7.15 - $10.84 $80,523 - $122,080
11,262 New
11,262 $104,000
Q2 2020

Aug 07, 2020

SELL
$8.05 - $14.21 $30,501 - $53,841
-3,789 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$6.8 - $14.66 $16,388 - $35,330
-2,410 Reduced 38.88%
3,789 $35,000
Q4 2019

Feb 06, 2020

BUY
$12.82 - $16.85 $29,780 - $39,142
2,323 Added 59.93%
6,199 $86,000
Q4 2019

Feb 04, 2020

SELL
$12.82 - $16.85 $4,730 - $6,217
-369 Reduced 8.69%
3,876 $43,000
Q3 2019

Nov 12, 2019

BUY
$16.31 - $28.29 $69,235 - $120,091
4,245 New
4,245 $73,000
Q4 2018

Feb 05, 2019

SELL
$8.59 - $18.05 $632,481 - $1.33 Million
-73,630 Closed
0 $0
Q3 2018

Nov 01, 2018

SELL
$17.11 - $21.74 $67,413 - $85,655
-3,940 Reduced 5.08%
73,630 $1.39 Million
Q2 2018

Aug 02, 2018

SELL
$16.76 - $23.92 $72,403 - $103,334
-4,320 Reduced 5.28%
77,570 $1.52 Million
Q1 2018

May 04, 2018

BUY
$16.16 - $31.31 $144,955 - $280,850
8,970 Added 12.3%
81,890 $1.54 Million
Q4 2017

Feb 01, 2018

BUY
$12.26 - $25.88 $893,999 - $1.89 Million
72,920
72,920 $1.21 Million

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $228M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.